# A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

> **NCT04090229** · PHASE1 · COMPLETED · sponsor: **ASLAN Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** ASLAN004
- **DRUG:** ASLAN004 Placebo

## Key facts

- **NCT ID:** NCT04090229
- **Lead sponsor:** ASLAN Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-09
- **Primary completion:** 2021-10-28
- **Final completion:** 2021-12-03
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04090229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04090229, "A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04090229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*